JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 29 No. 11 1810-1816
© 1988 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blend, M.J.
Right arrow Articles by Das Gupta, T.K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blend, M.J.
Right arrow Articles by Das Gupta, T.K.

Improved Sarcoma Imaging and Reduced Hepatic Activity with Indium-111-SCN-Bz DTPA Linked to MoAb 19–24

M.J. Blend, J.A. Greager, R.W. Atcher, J.M. Brown, M.W. Brechbiel*, O.A. Gansow and T.K. Das Gupta

Michael Reese Hospital, Chicago, Illinois
University of Illinois at Chicago, Chicago, illinois
Argonne National Laboratory, Argonne, illinois
Radiation Oncology Branch, National Institutes of Health, Bethesda, Maryland

Correspondence: For reprints contact: Michael J. Blend, PhD, DO, Associate Director, Div. of Nuclear Medicine, Michael Reese Hospital, Lake Shore Drive at 31st St., Chicago, IL 60616.

ABSTRACT

A murine monoclonal antibody (MoAb 19–24) directed against a human sarcoma antigen was prepared and labeled with 111ln by use of the linker 1-(p-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (SCN-Bz-DTPA). Imaging and biodistribution of this radioimmunocomplex were evaluated. MoAb P3 was similarly labeled as a negative control. Of 24 athymic mice bearing s.c. human fibrosarcoma, 12 received 10 µCi of [111ln]MoAb 19–24 and 12 received 10 µCi of [111ln]MoAb P3. The mice were imaged at 24, 48, 68, or 168 hr, after i.p. injection. Region of interest and biodistribution analysis showed maximum localization of MoAb 19–24 in the tumor at 72 hr with maximum liver localization of 24 hr. Analysis of MoAb P3 showed maximum tumor and liver activity at 24 hr. Tumor specificity studies were also conducted in three nude mice bearing a sarcoma in the left flank and a Burkitt's lymphoma in the right flank. Selective uptake was seen in the sarcoma but not in the lymphoma. The excellent uptake of [111In]SCN-Bz-DTPA-MoAb 19–24 in sarcoma without appreciable liver activity indicates that it may be a useful tumor imaging agent in man.

FOOTNOTES

* Present address: M. W. Brechbiel, Centocor, 244 Great Valley Parkway, Malvern, PA 19355.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. E. Milenic, K. Garmestani, E. D. Brady, P. S. Albert, D. Ma, A. Abdulla, and M. W. Brechbiel
Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease
Clin. Cancer Res., December 1, 2004; 10(23): 7834 - 7841.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1988 by the Society of Nuclear Medicine.